Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06364917 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | recruiting | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06866717 | Hybrid Prehabilitation Before Thoracic Surgery(HYBREATH) | recruiting | N/A | 38 | ADIR AssociationOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07416994 |
| Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer |
| recruiting |
| Phase 3 |
| 440 |
| MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY |
| 1 |
| Jun 15, 2026 |
| clinicaltrials |
| NCT00991094 | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06957314 | A Study of Hospital-at-Home for People Receiving Tarlatamab | recruiting | N/A | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07091305 | A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641023 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04332367 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | recruiting | Phase 2 | 59 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05419076 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07638891 | A Study of HDM2020 in Patients With Advanced Sq-NSCLC | recruiting | Phase 1 | 150 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05254782 | Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection | recruiting | — | 360 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07267000 | EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER(ImmuEX) | recruiting | N/A | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07637448 | EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC | recruiting | Phase 2 | 32 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07637474 | Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients | recruiting | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07633626 | Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib | recruiting | — | 24 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07485452 | Boosting Osimertinib Blood Brain Barrier Penetration(OSIBBBOOST) | recruiting | Phase 2 | 7 | Maastricht University Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07629375 | Standardization of a Platform of Preclinical Models Derived From NSCLC Patients | recruiting | — | 5 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03774758 | Biomarkers for Risk Stratification in Lung Cancer | recruiting | — | 590 | University of California, San FranciscoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | recruiting | Phase 1 / Phase 2 | 41 | OSE ImmunotherapeuticsINDUSTRY | 3 | Jun 4, 2026 | clinicaltrials |
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | recruiting | Phase 1 | 150 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626736 | Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC | recruiting | N/A | 300 | Wen-zhao ZHONGOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03958565 | Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. | recruiting | — | 100 | University of Colorado, DenverOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07359040 | Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer | recruiting | — | 80 | Peking University People's HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05703516 | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | recruiting | — | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05679349 | Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking | recruiting | N/A | 822 | Ronald MyersOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2026source: clinicaltrials